ArticleAmerican journal of translational research2025
Evaluation of the combined use of linaclotide and probiotics on clinical treatment efficacy and quality of life in patients with constipation-predominant irritable bowel syndrome.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of combining linaclotide with Bifid Triple Viable Capsules on clinical outcomes and quality of life (QoL) in patients with constipation-predominant irritable bowel syndrome (IBS-C).
methodsA retrospective analysis was performed on data from 189 IBS-C patients treated between April 2021 and January 2024. The control group (91 patients) received linaclotide, while the combined group (98 patients) received linaclotide plus Bifid Triple Viable Capsules. Outcomes assessed included bowel movement frequency, stool consistency scores, constipation severity, anxiety (Self-Rating Anxiety Scale, SAS), depression (Self-Rating Depression Scale, SDS), QoL (Irritable Bowel Syndrome Quality of Life, IBS-QoL), and symptom severity (Irritable Bowel Syndrome Severity Scoring System, IBS-SSS). Logistic regression identified independent risk factors for QoL improvement.
resultsBoth groups showed significant increases in bowel movement frequency after treatment (P < 0.001). The combined group experienced a significantly greater improvement compared to the control group (P < 0.001). Stool consistency scores improved significantly in both groups (P < 0.001), but no significant difference was observed between groups (P > 0.05). Both groups showed significant reductions in constipation severity, with the combined group showing greater improvement (P < 0.001). SAS and SDS scores decreased significantly in both groups (P < 0.001). The combined group showed greater reductions in SAS (P < 0.05) and SDS (P < 0.001). IBS-QoL scores improved significantly in both groups, with the combined group achieving greater improvement (P < 0.001). IBS-SSS scores decreased significantly, with the combined group experiencing a greater reduction (P < 0.001). IBS-QoL scores were positively correlated with bowel movement frequency (r = 0.289, P < 0.001) and negatively correlated with stool consistency scores (r = -0.154, P = 0.036), constipation severity (r = -0.386, P < 0.001), SDS scores (r = -0.150, P = 0.040), and IBS-SSS scores (r = -0.347, P < 0.001). Logistic regression identified treatment regimen (OR = 0.163, P = 0.017), age (OR = 4.666, P = 0.002), monthly income (OR = 0.065, P < 0.001), post-treatment bowel movement frequency (OR = 0.055, P < 0.001), and post-treatment constipation severity (OR = 5.545, P = 0.007) as independent factors influencing QoL improvement.
conclusionThe combined use of linaclotide and Bifid Triple Viable Capsules significantly enhances bowel movement frequency, reduces constipation severity, and improves QoL and psychological well-being in IBS-C patients. This approach offers a promising strategy for the comprehensive management of IBS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.